Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 3, 2000, Pages 345-352

  Pan, W J ^a   Goldwater, D R ^b   Zhang, Y ^a   Pilmer, B L ^c   Hunt, R H ^d  

^a ABBOTT LABORATORIES   (United States)

^b LAB Pharmacological Research International Inc   (Canada)

^c TAP Holdings Inc   (United States)

^d Abbott Laboratories ^*

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; PANTOPRAZOLE; THEOPHYLLINE;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG TOLERABILITY; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLOW RELEASE FORMULATION; THEOPHYLLINE BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; ANTI-ULCER AGENTS; AREA UNDER CURVE; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; BRONCHODILATOR AGENTS; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; SINGLE-BLIND METHOD; SULFOXIDES; THEOPHYLLINE;

EID: 0034013490     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00703.x     Document Type: Article

References (24)

1. 1 Michalets EL. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18: 84-112.
2. 2 Parsons ME. Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. Eur J Gastroenterol Hepatol 1996: 8(Suppl. 1): S15-20.
3. 3 Jenne JS, Murphy SA (eds). Drug Therapy for Asthma: Research and Clinical Practice. New York: Marcel Dekker, 1987.
4. 4 Kelly HW. Controversies in asthma therapy with theophylline and the β2-adrenergic drugs in the management of asthma. Clin Pharm 1984; 3: 386-95.
5. 5 Schuirman DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-80.
6. 6 Steinijans VW, Hartmann M, Huber R, Radtke HW. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 1991; 29: 323-8.
7. 7 SAS Institute. The GLM Procedure. In: SAS/STAT User's Guide. Volume 2, version 6, 4th edn. Cary, NC: SAS Institute, 1990: 891-996.
8. 8 Regardh CG, Andersson T, Lagerstrom PO, et al. The pharmacokinetics of omeprazole in humans: a study of single intravenous and oral doses. Ther Drug Monit 1990; 12: 163-72.
9. 9 Tateno M, Nakamura N. Phase I study of lansoprazole (AG-1749) antiulcer agent: capsule form. Rinsho Iyaku 1991; 7: 51-62.
10. 10 Steinijans VW, Huber R, Harmann M, et al. Lack of pantoprazole drug interactions in man. Int J Clin Pharmacol Ther 1994; 32: 385-99.
11. 11 Andersson T, Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36: 521-30.
12. 12 Andersson T, Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 1994; 37: 597-604.
13. 13 Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 1996; 277: 805-16.
14. 14 Huber R, Kohl B, Sachs G, et al. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995; 9: 363-78.
15. 15 Schultz HU, Hartmann M, Steinijans VW, et al. Lack of influence of pantoprazole on the disposition kinetics of theophylline in man. Int J Clin Pharmacol Ther Toxicol 1991; 29: 369-75.
16. 16 Andersson T, Holmberg J, Röhss K, Walan A. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol 1998; 45: 369-75.
17. 17 Ha HR, Chen J, Freiburghaus AU, Follath F. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 1995; 39: 321-6.
18. 18 Tjia JF, Colbert J, Back DJ. Theophylline metabolism in human liver microsomes: Inhibition studies. J Pharmacol Exp Ther 1996; 276: 912-7.
19. 19 Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole, and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996; 8(Suppl.): S21-5.
20. 20 Granneman GR, Karol MD, Locke CS, Cavanaugh JH. Pharmacokinetic interaction between lansoprazole and theophylline. Ther Drug Monit 1995; 17: 460-4.
21. 21 Upton RA. Pharmacokinetic interactions between theophylline and other medications (Part I). Clin Pharmacokinet 1991; 20: 66-80.
22. 22 Kokufu T, Ihara N, Sugioka N, et al. Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol 1995; 48: 391-5.
23. 23 Zimmerman AE, Katona BG. Lansoprazole: a comprehensive review. Pharmacotherapy 1997; 17: 308-26.
24. 24 Curi Pedrosa R, Daujat M, Pichard L, et al. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther 1994; 269: 384-92.